Background: Inflammatory Bowel Disease (IBD) frequently occurs in females of childbearing age. It is important to have the disease in remission at the time of conception and throughout the pregnancy. The benefits of medical therapy to maintain remission during pregnancy outweigh the risks of cessation in majority of the cases. Physicians involved in the care of pregnant IBD patients may not have the correct information regarding the safety of IBD drugs. We conducted a local survey to assess the knowledge and awareness among various practitioners regarding the safety issues of drugs used to treat IBD in the pregnant patients. Methods: 111 practitioners (Family Medicine (FM) n=35, Internal Medicine (IM) n=22, OB/GYN n=22, GI-General n=23, and GI-IBD Specialist n=9) were quizzed on the FDA classification of common IBD drugs and the need for caution with live vaccines in neonates of mothers receiving biologics during pregnancy. They were also given two scenarios in managing a patient with IBD desiring to become pregnant: 1) the patient being managed with thiopurines and 2) the patient being managed with biologics. For each scenario, physicians were asked if they would inform the patient to 1) only take current medications as symptoms arise, 2) not take the medications under any condition, 3) continue taking the medication as previously prescribed, 4 and 5) discontinue one and start a differentmedication. The percentage of practitioners among the different groups was compared using either χ2 or Fisher's exact test as appropriate. The p-value was adjusted for multiple comparisons. Results: GI-General and IM were less likely to answer correctly more than one question regarding the FDA classification of IBD drugs compared to FM and OB/GYN practitioners (27% vs. 74%, p,0.0005) and GI-IBD (27% vs. 56%, p=0.43). GIs (GI-General and GIIBD) are more likely to advise their patients to continue taking their current medications (biologics and thiopurines) during pregnancy compared to non GIs (IM, FM, OB/GYN) (biologics: 84% vs. 45%, p,0.0005; thiopurines: 66% vs. 14%, p,0.0005)( figure). Only 45% of OB/GYN correctly identified the safety issues regarding administration of live vaccines in neonates of mothers receiving biologics. There was no difference between GIs and non GIs with regard to the safety knowledge of administering live vaccines (63% vs. 59%, p= 0.83). Overall, 79% of physicians surveyed said they would change their practice based on the educational section at the end of the survey. Conclusion: Practitioners involved in the care of pregnant patients may not have the correct knowledge regarding the safety and management of IBD drugs during pregnancy. Bringing awareness through appropriate education can result in the greater likelihood of physicians following best practice guidelines.